{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:29:38Z","timestamp":1788971378983,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T00:00:00Z","timestamp":1512950400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ijcard.2017.09.027","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T10:46:55Z","timestamp":1505904415000},"page":"261-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up"],"prefix":"10.1016","volume":"249","author":[{"given":"M.","family":"Siegenthaler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Huynh-Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Krayenbuehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Widmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Debaix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Olinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Namdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ruschitzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijcard.2017.09.027_bb0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.ijcard.2017.09.027_bb0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10545-014-9677-8","article-title":"Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages","volume":"37","author":"Rombach","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7","key":"10.1016\/j.ijcard.2017.09.027_bb0015","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.ijcard.2017.09.027_bb0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.ijcard.2017.09.027_bb0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/heartjnl-2014-306278","article-title":"Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease","volume":"101","author":"Talbot","year":"2015","journal-title":"Heart"},{"issue":"19","key":"10.1016\/j.ijcard.2017.09.027_bb0030","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","article-title":"Cardiorenal syndrome","volume":"52","author":"Ronco","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2017.09.027_bb0035","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10741-015-9500-0","article-title":"Fabry's disease: an example of cardiorenal syndrome type 5","volume":"20","author":"Sharma","year":"2015","journal-title":"Heart Fail. Rev."},{"issue":"8","key":"10.1016\/j.ijcard.2017.09.027_bb0040","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cardfail.2007.04.008","article-title":"Worsening renal function and prognosis in heart failure: systematic review and meta-analysis","volume":"13","author":"Damman","year":"2007","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ijcard.2017.09.027_bb0045","first-page":"w14051","article-title":"The cardiorenal problem","volume":"144","author":"Pollock","year":"2014","journal-title":"Swiss Med. Wkly."},{"issue":"4","key":"10.1016\/j.ijcard.2017.09.027_bb0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.ijcard.2017.09.027_bb0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcard.2017.09.027_bb0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/ejechocard\/jep007","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography","volume":"10","author":"Nagueh","year":"2009","journal-title":"Eur. J. Echocardiogr."},{"issue":"4","key":"10.1016\/j.ijcard.2017.09.027_bb0065","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"4","key":"10.1016\/j.ijcard.2017.09.027_bb0070","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/01.CIR.55.4.613","article-title":"Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method","volume":"55","author":"Devereux","year":"1977","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ijcard.2017.09.027_bb0075","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.ijcard.2017.09.027_bb0080","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2010.03.026","article-title":"Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60mL\/min\/1.73m2","volume":"56","author":"Stevens","year":"2010","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.ijcard.2017.09.027_bb0085","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"issue":"16","key":"10.1016\/j.ijcard.2017.09.027_bb0090","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/heartjnl-2015-308897","article-title":"The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy","volume":"102","author":"Schmied","year":"2016","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.ijcard.2017.09.027_bb0095","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1161\/HYPERTENSIONAHA.112.195685","article-title":"Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine","volume":"60","author":"Rombach","year":"2012","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.ijcard.2017.09.027_bb0100","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry","volume":"57","author":"Patel","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2017.09.027_bb0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2004.01.011","article-title":"Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts","volume":"82","author":"Lucke","year":"2004","journal-title":"Mol. Genet. Metab."},{"issue":"11","key":"10.1016\/j.ijcard.2017.09.027_bb0110","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.humpath.2015.07.017","article-title":"Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy","volume":"46","author":"Chimenti","year":"2015","journal-title":"Hum. Pathol."},{"issue":"2","key":"10.1016\/j.ijcard.2017.09.027_bb0115","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","article-title":"Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy","volume":"1822","author":"Biancini","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"12","key":"10.1016\/j.ijcard.2017.09.027_bb0120","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.ijcard.2017.09.027_bb0125","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am. J. Cardiol."},{"issue":"Suppl. 2","key":"10.1016\/j.ijcard.2017.09.027_bb0130","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1097\/01.ASN.0000016684.07368.75","article-title":"Renal pathology in Fabry disease","volume":"13","author":"Alroy","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.ijcard.2017.09.027_bb0135","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","article-title":"Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)","volume":"25","author":"Fogo","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"issue":"12","key":"10.1016\/j.ijcard.2017.09.027_bb0140","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.echo.2013.08.024","article-title":"Left atrial enlargement and reduced atrial compliance occurs early in Fabry cardiomyopathy","volume":"26","author":"Boyd","year":"2013","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"7","key":"10.1016\/j.ijcard.2017.09.027_bb0145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J. Med. Genet."},{"issue":"5","key":"10.1016\/j.ijcard.2017.09.027_bb0150","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"Tondel","year":"2008","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.ijcard.2017.09.027_bb0155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000369309","article-title":"Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria","volume":"129","author":"Tondel","year":"2015","journal-title":"Nephron"},{"issue":"4","key":"10.1016\/j.ijcard.2017.09.027_bb0160","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","article-title":"Cardiac manifestations of Anderson-Fabry disease in children and adolescents","volume":"97","author":"Kampmann","year":"2008","journal-title":"Acta Paediatr."},{"issue":"4","key":"10.1016\/j.ijcard.2017.09.027_bb0165","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ijcard.2017.09.027_bb0170","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"Tondel","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2017.09.027_bb0175","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1750-1172-7-91","article-title":"Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies","volume":"7","author":"Germain","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ijcard.2017.09.027_bb0180","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.ijcard.2017.09.027_bb0185","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","author":"Hughes","year":"2016","journal-title":"J. Med. Genet."},{"issue":"9","key":"10.1016\/j.ijcard.2017.09.027_bb0190","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ijcard.2017.09.027_bb0195","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ijcard.2017.09.027_bb0200","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00431-017-2950-8","article-title":"Newborn screening for Fabry disease in the north-west of Spain","volume":"176","author":"Colon","year":"2017","journal-title":"Eur. J. Pediatr."},{"issue":"7\u20138","key":"10.1016\/j.ijcard.2017.09.027_bb0205","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.clinbiochem.2014.02.014","article-title":"Fabry disease: a new approach for the screening of females in high-risk groups","volume":"47","author":"Pasqualim","year":"2014","journal-title":"Clin. Biochem."},{"issue":"1","key":"10.1016\/j.ijcard.2017.09.027_bb0210","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12881-016-0309-z","article-title":"Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles","volume":"17","author":"Oder","year":"2016","journal-title":"BMC Med. Genet."},{"issue":"6","key":"10.1016\/j.ijcard.2017.09.027_bb0215","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/eurjhf\/hfq073","article-title":"Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women","volume":"12","author":"Havndrup","year":"2010","journal-title":"Eur. J. Heart Fail."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527317326992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527317326992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T18:47:34Z","timestamp":1570128454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527317326992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":43,"alternative-id":["S0167527317326992"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2017.09.027","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2017.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}